# Extracted from: GTG 2011 - Pregnancy and Breast Cancer.pdf
# Guideline ID: gtg-2011-pregnancy-and-breast-cancer
# Content length: 46493 characters
# Processing date: 1732953490.8998735

Pregnancy and Breast Cancer
Green–top Guideline No. 12
March 2011PregnancyandBreastCancer 
ThistitlewasfirstpublishedasRCOGadvicein1997andsubseque ntlyasaGreen-topGuidelineinJanuary 
2004.Thisdocumentisthesecondeditionoftheguidelineandupdatestheprevious 2004edition. 
1. Purposeandscope 
Thisdocumentaimstoprovideclinicalguidancetohealthprofessionalscaringforwomenofchildbearin g 
agewithadiagnosisorhistoryofbreastcancer.Themanagement ofpregnancy inrelationtobreastcancer 
ismultidisciplinary.Theguidelinewillbeofvaluetoobstetriciansandgynaecologists,fertilityspecialists 
andmidwivesaswellasoncologistsandbreastcarenurses. 
2. Background 
Breastcanceristhemostcommoncancerinfemales,withalifetimeriskofoneinnineintheUK,andis 
theleadingcauseofdeathinwomenaged35 –54years.Fifteenpercentofcasesarediagnosedbeforethe 
ageof45years,thusbreastcanceraffectsalmost5000womenofreproductiveageintheUKannually. 
Between1991and1997therewere1.3 –2.4casesofbreastcancerinwomenper10000livebirths ,1,2 
althoughwhenbreastcancerisdiagnosedinwomenaged30yearsorless,10 –20%ofcasesmaybe 
associatedwithpregnancyoroccurwithin1yearpostpartu m.
Theprognosisofbreastcancerisimproving ,with5-yearsurvivalaround 80%fortheunder50sagegroup; 
however,thesurvivalratemaybelowerinveryyoungwomen .3Treatmentofpregnancy-associatedcancer 
shouldbeinamultidisciplin aryteamaccordingtostandard UKguidelines 4withinclusionoftheobstetric 
teamascoremembers. 
Fewerthan10%ofwomendiagnosedwithbreastcancersubsequentlybecomepregnant, 5,6 butincreasing 
numbersofwomenareseekingpregnancyfollowingtreatment.Youngwomenpresentingwithbreast 
canceroftenhavefertility-rel atedconcerns 7–9 andneedwell-informeddiscussionsonfertility,pregnancy 
andlactationafterbreastcancerandtheavailability offertilitypreservationprocedures.
3. Identification andassessment ofevidence 
Thisguidelinewasdevelopedinaccordancewithstandard methodologyforproducingRCOGGreen-top 
Guidelines .Medline,Pubmed,allEBMreviews(CochraneCRCT,CochraneDatabaseofSystematicReviews, 
Methodologyregister ,ACPjournalclub ,DARE,HTA,MaternityandInfantCare),EMBASEandTRIPwere 
searchedforrelevantrandomisedcontrolledtrials,systematicreviewsandmeta-analyses,cohortstudiesand 
casestudies.Thesearchwasrestrictedtoarticlespublishedbetween2002and December 2009 ,updated 
fromtheoriginalsearchforthepreviousedition.Thesearchtermsincludedwere:‘breastneoplasms ’, 
‘breastcancer’,‘pregnancy’,‘pregnancycomplications’, ‘breastcancerandfertility’,‘mastectomy ’,‘ breast -
feeding ’,‘ lactation ’, ‘contraception’, ‘fertility ’and ‘infertility’.Abstracts wereusedtoidentifykeyarticles.The 
NationalLibraryforHealthandtheNationalGuidelines ClearingHouseweresearched forrelevant 
guidelines. 
Incontrasttotheextensiveliteratureontreatmentofbreastcancer,thereisnolevel1evidence on 
pregnancyandbreastcancer.Therearesomewell-desig nedobservationalstudies.Thus ,recommendations 
forpracticearelimitedtogradeC/Dbut ,wherepossible, recomme ndationsarebasedon,andexplicitly 
linkedto,theevidencethatsupportsthem.Areaslackingevidencearehighlightedandannotatedas‘good 
practicepoints ’. 
RCOGGreen-topGuidelineNo.12 2of15 ©RoyalColle geofObste tricians andGynaecologis ts 4. Whatistheoptimalmanagement ofbreast cancerdiagnosedduringpregnancy? 
4.1 Prognosis 
Pregnancyitselfdoesnotappeartoworsentheprognosis forwomendiagnosedinpregnancy 
comparedwith non-pregnantcontrols matchedforageandstage 10 (providedthatstandard 
treatmentguidelinesforthebreastcancerareadheredto ).
However,aspregnancy-associatedbreastcanceroccursinayoungerpopulationwhomayhave 
featuresthatcarryahigherriskofmetastasessuchashigh -gradetumoursandestrogen receptor 
negativetumours,theseyoungerwomenmaybeexpectedtohaveaninferiorprognosis .11,12 
4.2 Diagnosis 
Womenpresentingwithabreastlumpduringpregnancyshouldbereferred toa 
breastspecialistteamandanyimagingorfurther testsshouldbeconductedin 
conjunctionwiththemultidisciplin aryteam. 
Diagnosismaybedifficultinwomenwhoarepregnant orlactating.Womenpresentingwithabreastlump 
duringpregnancyshouldbereferredtoabreastspecialistteamandanyimagingorfurthertestsshould 
beconductedwithinthebreastmultidisciplinaryteam.Womenshouldhaveadesignated keyworker, 
usuallyabreastcarenurse.Ultrasoundisusedfirsttoassessadiscretelump,butifcancerisconfirmed ,
mammographyisnecessary (withfetalshielding)toassesstheextentofdiseaseandthecontralateral 
breast.Tissuediagnosisiswithultrasound -guidedbiopsyforhistologyratherthancytology ,asproliferative 
changeduringpregnancy renderscytologyinconclusive inmanywomen.Histologyissimilartothatinage-
matchednon-pregnantcounterparts :histologicalgrade,receptorstatusandhumanepidermalgrowth 
factorreceptor2(HER2 )informtreatmentplanning. Stagingformetastasesisconducte donlyifthereis 
highclinicalsuspicionandshouldcomprisechestX-rayandliverultrasound ifpossible.Gadolinium-
enhancedmagneticresonanceimagingis notrecommendedunlessthereisaspecificneedforitto 
investigateaclinicalproblem ;therearelimiteddatafortheuseofthisimagingmethodinpregnancy, 
althoughnoadverseeffectsofgadoliniumonthefetushavebeenreported .13 Tumourmarkerssuchas 
CA15-3,CEAandCA125arenotusedinearlybreastcancerand maybemisleadinginpregnancy,andare 
notrecommended. 
BonescanningandpelvicX-raycomputedtomographyarenotrecommended 
becauseofthepossibleeffectofirradiationonthefetus .
Inwomenwhoarenotpregnant, X-raycomputedtomography(CT )andisotopebonescanarethe 
preferredmethodsofinvestigationtoestablish orexcludemetastases.Thesemethodsarenotappropriate 
inwomenwhoarepregnant,inwhomchestX-rayandliverultrasoundarepreferred. Ifthereisconcern 
aboutboneinvolvement,aplainfilmoftherelevantareaand/ormagneticresonanceimagingtominimise 
radiationexposuretothefetusissuggested. 
4.3Considerationofterminat ionofpregnancy 
Thedecisiontocontinuethepregnancyshouldbebasedoncarefuldiscussion ofthe 
cancerprognosis,treatmentandfuturefertilitywiththewomanandherpartnerand 
multidisciplinaryteam .
4.4Treatmentduringpregnancy 
Themultidisciplinaryteamreviewoutcome shouldbeforwardedtotheobstetricteam 
andfamilydoctor. 
©RoyalCollegeofObst etriciansandGynaecologists 3of15 RCOGGreen-topGuidelineNo.12 Evidence 
level2 –
Evidence 
level2+/3 
/check
/check
/check
/checkSurgicaltreatmentincludingloco -regionalclearance canbeundertakeninalltrimesters.Breast-
conservingsurgeryormastectomycanbeconsidered ,basedontumourcharacteristics and 
breastsize ,followingmultidiscipl inaryteamdiscussion. Reconstructionshouldbedelayedto 
avoidprolongedanaesthesiaandtoallowoptimalsymmetrisati onofthebreastsafterdelivery. 
Sentinelnodeassessmentusingradioisotope scintigraphydoesnotcausesignificantuterine 
radiation ,14 butbluedyeisnotrecommendedastheeffectuponthefetusisunknown .Sentinel 
nodebiopsyisindicatedinwomenwhohaveanegative resultfromapreoperativeaxillary 
ultrasoundandneedlebiopsy.Iftheaxillaispositive ,axillaryclearanceisindicated. 
Radiotherapyiscontraindicateduntildeliveryunlessitislife savingortopreserveorganfunction(e.g. 
spinalcordcompression).Ifnecessary ,radiotherapycanbeconsideredwithfetalshielding or,depending 
ongestationalage,earlyelectivedeliverycouldbediscussed.Routinebreast/chestwallradiotherapy can 
bedeferreduntilafterdelivery .
Systemicchemotherapyiscontraindicatedinthefirsttrimester becauseofahighrateoffetal 
abnormality ,butissafefromthesecondtrimesterandshouldbeofferedaccordingtoprotocols 
definedbytheriskofbreastcancerrelapseandmortality.Anthracylineregimens aresafe;there 
arefewerdataontaxanes ,whichshouldbereservedforhigh -risk(node -positive)ormetastatic 
disease .15–17 Standardantiemeticsincluding5HT3 serotonin antagonistsanddexamethasone 
shouldbeused.Therearenodataonaneurokinin recptorantagonistwithveryhighefficacyin 
chemotherapy -inducedemesis .Thereisnoevidence foranincreasedrateofsecond-trimester 
miscarriageorfetalgrowthrestriction,organdysfunctionorlong -termadverseoutcomewith 
theuseofchemotherapy .17,18 
Forwomeninwhomtumourcharacteristics,definedbyimagingandcorebiopsy,meanthatchemothera py 
isindicated,adecisionmaybemadetoofferneoadjuvantchemotherapybeforesurgerytoallowtumour 
downstagingandtofacilitatesurgery.Occasionally ,withalow -risktumourinwhichchemotherapyisnot 
indicated ,theremaybeanindicationformastectomy. Inthissituationradiotherapywouldbedeferred. 
Tamoxifenandtrastuzumabarecontraindi catedinpregnancyandshouldnotbe 
used. 
Tamoxifenisnotuseduntilafterdelivery.Trastuzumab,amonoclonalantibodytargetedagainst 
theHER2/neureceptor, iscontraindicatedduringpregnancy becauseofreportedadversefetal 
outcome .19,20 Therearenodataonothertargetedtherapies suchasvascularendothelialgrowth 
factorantagonists ,includingbevacizumab.However, therearenocompellingoncological 
reasonsforuseoftargetedtherapiesincludingmonoclonalantibodiesorsmall-molecule tyrosine 
kinaseinhibitorsduringpregnancyasconventionalchemotherapy canbeused ,allowingthese 
drugstobereservedforpostpartum.Haemopoietic growthfactors(granulocytecolony-
stimulatingfactor)maybeemployedtoamelioratechemother apy-inducedneutropenia and 
havebeenusedextensivelyinhaematologicalmalignancy;theiruseisrecommendedto 
minimisepotentialmaternalandfetalproblemsassociatedwithneutropenia .21 Useoftheseand 
otherdrugsshouldbediscussedwiththeobstetrician. 
4.5Timingofdeliveryofthebaby 
Thebirth ofthebabyshouldbetimedafterdiscussionwiththewomanandthe 
multidisciplinaryteam .
Mostwomencangotofulltermofpregnancyandhaveanormalorinduceddelivery.Ifearlydeliveryof 
thebabyisnecessary ,considerationofcorticosteroidsforfetallungmaturationisappropriate.However, 
birthshouldbemorethan2 –3weeksafterthelastchemotherapy sessiontoallowmaternalbonemarrow 
recoveryandtominimiseproblemswithneutropenia.
RCOGGreen-topGuidelineNo.12 4of15 ©RoyalColle geofObste tricians andGynaecologis ts Evidence 
level4 
Evidence 
level3 
D
Evidence 
level3 
/check4.6Lactation 
Womenshouldnotbreastfeedwhentakingtrastuzumab(Herceptin®,Roche)or 
tamoxifen,asitisunknownwhetherthesedrugsaretransmitted inbreastmilk.
Theabilitytobreastfeedmaydependonsurgeryandwhethermajorducts havebeenexcised. 
Breastfeedingwhileonchemotherapyisnotadvised,asthedrugscrossintobreastmilkandmay 
causeneonatalleucopeniawithariskofinfection.Thereshouldbeatimeintervalof14daysor 
morefromthelastchemotherapy sessiontostartofbreastfeedingtoallowdrugclearance from 
breastmilk .22 
Ifchemotherapyisrestarted ,breastfeedingmustcease.Ashortperiodoflactation maybe 
psychologicallybeneficialafterastressfulpregnancy andbebeneficialtothebaby .23 Women 
takingtamoxifenshouldnotbreastfeed. 
Womenshouldnotbreastfeedwhentakingtrastuzumab asitisunknownwhetherthisdrugistransmitte d 
inbreastmilk .
5. Whatarethecontraceptive choices forwomen wish ingtoavoidpregnancyafter 
treatmentofbreastcancer? 
Non-hormonalcontraceptivemethodsarerecomm ended. 
Womenwithahistoryofbreastcancershouldseekspecialist contraceptiveadvice.Hormonal 
contraceptio niscontraindicatedinwomenwithcurrentorrecentbreastcancer(WorldHealth 
Organization/UK medicaleligibilitycategory4) .24 Thisadvicedoesnotdifferentiatebetween 
hormone-sensitiveandhormone-insensitive tumours.Although hormona lcontraceptionmay 
beconsideredafteratleast5yearsfreeofrecurrence(WorldHealthOrganization/UK category 
3) 24 andcurrentevidenceallaysconcernsthatlong-termoralcontraceptiveuseaffectsbreast 
cancerrisk, 25,26 thereisinsufficientevidencetosupporttheuseofcombinedorprogestogen-
onlyhormonal contraceptiveswhenalternativenon-horm onalmethodsaresuitableand 
acceptable. 
Thelevonorgestrelintrauterinesystem(LNG-IUS :Mirena®, BayerHealthcarePharmaceuticals) 
mayreducetheriskofendometrialabnormaliti esduringtamoxifen therapy ,27 butfurther 
evidenceisrequiredonitssafetyinbreastcancersurvivors.Nooverallincreaseinrecurrence 
riskwasfoundinaretrospectivecontrolledcohortstudy ofLNG-IUSuserscomparedwithnon-
users(adjustedhazardratio1.86 ,95%CI0.86 –4.00), 28 althoughsubgroupanalysissuggesteda 
higherrecurrencerisk ,whichwasofborderlinesignificance ,inwomenwhodeveloped breast 
cancerwhileusingLNG -IUSandcontinued itsuse(adjustedhazardratio3.39,95%CI1.01– 
11.35). 28 
6. Whatadviceshou ldbegiventowomen planni ngpregnancyfollowi ngbreastcancer?
Womenplanningapregnancyaftertreatment forbreastcancershouldconsulttheir 
clinicaloncologist,breastsurgeonandobstetrician. 
Womenontamoxifenareadvisedtostopthistreatment3monthsbeforetryingtoconceivebecauseof 
thelonghalf -lifeofthedrug, and tohaveanyroutineimagingbeforetryingtoconceivetoavoidtheneed 
forimagingduringpregnancy.Womenwithmetastati cdiseaseshouldbeadvisedagainstafurther 
pregnancyaslifeexpectan cyislimitedandtreatmentofmetastaticdiseasewouldbecompromised. The 
remainderofthissectionconcernswomentreatedforearly -stagedisease. 
©RoyalCollegeofObst etriciansandGynaecologists 5of15 RCOGGreen-topGuidelineNo.12 /check
Evidence 
level3 
Evidence 
level4 
/check
Evidence 
level4 
Evidence 
level2+ 
/check6.1Impactofpregnancy onriskofrecurrence 
Womencanbereassuredthatlong-termsurvival afterbreastcancerisnotadversely 
affectedbypregnancy . 
Sincemanybreastcancersareestrogen receptorpositiveandendocrineresponsive,womenusedtobe 
advisedagainstpregnancybecauseofconcerns thatitwouldworsenprognosis.However,theevidence 
fromthepublishedstudiesisreassuring,showing eithernoimpactonsurvivalorimprovedsurvival. 
Despitethelimitationsofthestudies,whicharemainlyretrospectivecase –controlserieswithlimited 
numbers,theyatleastdemonstratethatoutcomeaftertreatmentforbreastcancerisnotadverselyaffected 
bypregnanc y .29,30 
Theprognosisisgoodforwomenwithasubsequentpregnancy afterearly -stagebreastcancer .31 –33 
Thepublishedseriesreflectanimprovementintreatmentoverrecentdecades. Arecent 
population-basedstudyinWesternAustraliafrom1982to2003reportedsurvivalratesof92% 
at5yearsand86%at10years .6
Severalstudiesshowbettersurvivaloutcomeinwomenwhoconceiveaftertreatmentforbreast 
cancer .5,6,32,34,35 Inthelargestseries,womenwhohadafull-termpregnancy( n=199)hada 
relativeriskofdeathof0.73(95%CI0.54 –0.99). 5Thesefindingsmaybeexplainedbyselection 
biasandthe‘healthymothereffect ’describedbySankila :36 healthywomenaremorelikelyto 
conceive,andwomenwithpoorprognosisorearlyrelapsedonotembarkuponpregnancy.
However ,someauthors postulateanactualprotective effectofpregnancy. 6,37 
Theimpactofpregnancy doesnotseemtobemodifiedbytumourcharacteristics(e.g.size, 
hormonereceptorstatus) ,5butthereareinsufficientdatatodrawfirmconclusions.Inwomen 
withBRCA genemutations,therisksassociated withsubsequentpregnancyareuncertain .38 
6.2 Timeintervalbeforepregnancy 
Adviceonpostponementofpregnancyshouldbeindividualisedandbasedon 
treatmentneedsandprognos isovertime.Mostwomenshouldwaitatleast2years 
aftertreatment,whichiswhentheriskofcancerrecurrence ishighest. 
Womenaregenerallyadvisedtowaitforatleast2yearsaftertreatmentforbreastcancerbefore 
conception 37,39–41 becauseoftheriskofearlyrelapse.Therateofdiseaserecurrenceishighest 
inthefirst3yearsafterdiagnosisandthen declines ,42 althoughlaterelapsesdooccurupto10 
yearsandmorefromdiagnosis .3
Womenwithestrogenreceptorpositivediseaseshouldbeadvisedthattherecommended duration of 
tamoxifentreatmentis5years. 
Thisadvicehasbeenchallengedbecauseofthelackofpublisheddatashowingthatpostponing 
pregnancyhasanimpactonoutcome ;6theliteratureonrecurrentdiseasealsoneedstobe 
reviewedinthelightofchangingtreatmentregimens andimprovedunderstandingofcancer 
subtypes.Ithasbeensuggestedthatwomenwithagoodprognosisneednotwait2yearsto 
becomepregnant .6
RCOGGreen-topGuidelineNo.12 6of15 ©RoyalColle geofObste tricians andGynaecologis ts C
Evidence 
level2+ 
Evidence 
level2+ 
Evidence 
level2+ 
/check
Evidence 
level3 
Evidence 
level2+ Anunderstandingoftheprognostic factorsaffectingtheindividualwoman –tumoursize,grade, 
nodalstatus,estrogenandprogesteronereceptor andHER2status–shouldenabletheoncologist 
togiveappropriateadvice. 43,44 Thisisofgreatimportancetothewomandesiringpregnancy,who 
mayneedtoweighupthebenefitofpostponing conception,forexampletocomplete 
prolongedadjuvanttherapywithtamoxifen, againsttheriskofinfertilityasaresultofdelay.
6.3Outcomeofpregnancy 
Themajorityofpregnanciesafterbreastcancerproceedtolivebirth.Theremaybeanincreased 
miscarriageratefollowingbreastcancer ,45 butthepublishedseriesaresmallandnotallreport 
maternalage(amajorriskfactorformiscarriage )ordistinguishbetweenspontaneous 
miscarriageandinducedtermination .31,46,47 Arecentlyreportedseriesof465pregnantwomen 
whowerebreastcancersurvivorsresultedin236full -termbirths(51%),36spontaneousmiscar -
riages(8%)and193inducedterminations (41%). 5Womenaremorelikelytoterminatea 
pregnancywhenitoccurssoonaftertreatmentorduringadjuvanttherapy. 5,6 
Womencanbereassuredconcerningtheriskofmalformation inchildrenconceive d 
aftertreatmentforbreastcancer .
Mostoftheavailabledatadonotshowanyincrease incongenitalmalformationsorstillbirth 
amongtheoffspringofwomenwhohavecompleted treatmentforbreastcancer .6,48,49 Alarge 
studyderivedfromtheDanishregistriesidentified216birthstowomenwithapriordiagnosis 
ofbreastcancerandfoundnostillbirths,noincreaseincongenitalanomaliesnoincreaseinlow 
birthweightandnosubstantialriskofpretermbirth(OR 1.3,95%CI0.7–2.2). 49 TheSwedish 
dataon331births,however,showedatendency towardsanincreasedriskofmalformations 
(OR2.1,95%CI1.2 –3.7),birthbefore32weeksofgestation (OR3.2,95%CI1.7 –6.0)andbirth 
weightbelow1500g(OR2.9,95%CI1.4 –5.8); 50 nevertheless ,adverseoutcomesareuncommon.
Theheritabilityofbreastcancerisasourceofanxietybutdoesnotaffectchildhoodhealth.Womenwho 
areknowntobebreastcancergene( BRCA )carriersmaywishtoconsiderpreimplantation genetic 
diagnosis,whichisnowavailableintheUK.However ,someyoungwomenwithafamilyhistoryindicative 
ofgeneticriskmaynotwishtoundergotestingsoasnottocompromisetheirdecisionsregardinghaving 
afamily.
7. Whatistheoptimalmanagement ofpregn ancyfollow ingtreatmentforbreast cance r?
Pregnancyfollowingbreastcancershouldbejointlysupervisedbytheobstetrician, 
oncologistandbreastsurgeon. 
Echocardiographyshouldbeperformedduringpregnancyinwomenatrisktodetect 
cardiomyopathythroughrestingleftventricularejectionfractionorechocardio -
graphicfractionalshortening. 
Duringpregnancy ,abreasttreatedbysurgery/radiotherapy maynotundergohormonalchangeandthe 
womanmayrequireatemporaryprosthesis.Ifbreastimagingisneeded ,ultrasound(performedthrough 
thebreastmultidisciplinaryteam)ispreferred.Metastatic relapsemaybehardertodetect andcommon 
complaintsinpregnancysuchasbackachecanbedifficulttoassess. 
Thesewomenmayhavereceivedadjuvantchemotherapy with anthracyclines(doxorubicin, epirubici n) ,
whichcancausecumulativedose-dependent leftventricular dysfunction and,rarely,cardiomyopathy .51,52 
Althoughcardiaccomplicationsduringpregnancyarerareincancersurvivors ,53 echocardiographyshould 
beperformedduringpregnancyinwomenatrisktodetectcardiomyopathythroughrestingleftventricular 
ejectionfractionorechocardiographicfractionalshortening . 
©RoyalCollegeofObst etriciansandGynaecologists 7of15 RCOGGreen-topGuidelineNo.12 Evidence 
level4 
Evidence 
level3 
D
Evidence 
level2+/3 
D/checkAslightlyincreasedriskofdeliverycomplications(OR1.5,95%CI1.2 –1.9)andcaesarean 
section(OR1.3,95%CI1.0 –1.7)hasbeenreportedinbreastcancersurvivors. 50 
Thesupervisionofpregnancyafterbreastcancershouldbeconsultant led,butmidwiferyinvolvementwill 
helptonormalisecare. 
8. Whatadviceshouldbegiven towomen wishingtobreastfe edfollow ingtreatmentfor 
breastcancer?
Womencanbereassuredthattheycanbreastfeed fromtheunaffectedbreast. 
Thereisnoevidencethatbreastfeedingincreasestheriskofrecurrenceinwomenwhohave 
completedtreatmentforbreastcancer.Onlyonestudyhasreportedonsurvivalinrelationto 
lactation ,32 andsuggestedthatbreastfeedingwasassociatedwithbettersurvivalthanbottle-
feeding. 
Breast-conservingsurgerymaynotinhibitlactationintheaffectedbreast,butradiotherapy 
causesfibrosis ,makinglactationunlikely .54–57 Thereisnoevidencethatpreviouschemotherapy 
affectsthesafetyofbreastfeeding. 
Inviewofthewell -recognisedbenefitsofbreastfeedingtothebaby ,23 womenwhowishtobreastfeed 
shouldbeencouragedtodoso. 39,58 Midwiferysupporthelpstoestablishsuccessfullactation. 59 
9. Whatistheeffectofbreast cancertreatment onthewoma n’sfertility? 
Theeffectoftreatmentonfertilityshouldbediscussed withallwomenofrepro-
ductiveagediagnosedwithbreastcancer,andwritteninformationshouldbe 
provided.Referraltoafertilityspecialis tshouldbeavailable .Specialistcounsell ing 
shouldbeavailable. 
Infertilityaftertreatmentisamajorconcernforyoungwomenwithbreastcancer .60–63 Inan 
Americansurveyof657womendiagnosedwithbreastcancerundertheageof40years,57% 
reported‘substantialconcern ’aboutbecominginfertileand29%statedthatitinfluencedtheir 
treatmentdecisions. 63 Inthissample,only51%feltthattheirconcernshadbeenadequately 
addressed,andseveralotherauthorshavenotedwomen’s frustrationwiththepaucityof 
informationavailable .64–66 Women’spreferredsourceofinformationonfertilityisconsultation 
withafertilityspecialistbackedupbyaninformati onbooklet. 64,67 
ArecentjointworkingpartyoftheRoyalColleges ofPhysicians ,RadiologistsandObstetricians 
andGynaecologistsintheUKrecommended thatpeoplewithcancershouldbefullyinformed 
ofpotentialgonadotoxicitybeforetreatment, andthatspecialistpsychological supportand 
counsellingshouldbeavailable. 68 
9.1 Whatistheeffectofadjuvant chemotherapyonfertility?
Chemotherapy-inducedgonadotoxicitymaycause permanen tamenorrhoea withcompleteloss 
ofgermcells ,transientamenorrhoea,menstrualirregularityandsubfertility .Thedegreeofgonado -
toxicityisdependentonthespecificagentsused,thecumulativedoseadministe redandthe 
woman’sage. Amenorrhoeaisreportedin20–70%ofpremenopausalwomenwithbreastcancer ,69 
buttheraterangesfromlessthan 5%inwomenunder30yearsofageto50%inwomenaged 
36 –40 years .70 Alkylatingagentssuchascyclophosphamidehavewell -recognisedgonadotoxicity, 
RCOGGreen-topGuidelineNo.12 8of15 ©RoyalColle geofObste tricians andGynaecologis ts Evidence 
level2+ 
Evidence 
level2+ /check
Evidence 
level3 
/check
Evidence 
level3 
Evidence 
level4 
Evidence 
level3 andtheclassicCMFregimen(cyclophosphamide,methotrexate, 5-fluorouracil)causesahigher 
incidenceofamenorrhoeathananthracycline-bas edregimenssuchasFEC(5-fluorouracil, 
epirubicin,cyclophosphamide) .71 Thenewertaxanesappeartobelessgonadotoxic .72 
9.2 Whatistheeffectofadjuvant hormon altherapyonfertility? 
Theagentsusedforadjuvanthormonaltherapydonotinthemselvescauselong-termeffectsonfertility. 
Tamoxifen(aselectiveestrogenreceptormodulator)oftencausesmenstrualirregularityandthereisan 
increasedriskofendometrialpathology;conceptionduringtamoxifentherapyshouldbeavoidedbecause 
ofpotentialteratogenicity ,anda‘washoutperiod ’of2–3monthsisadvised.Gonadotrophin-releasing 
hormone(GnRH)analoguescauseamenorrhoea andprofoundestrogen deficiency;womenmayfindthe 
menopausalsymptomsworrying ,buttheeffectisentirelyreversible.Trastuzumabisamonoclonalantibody 
thatbindsselectivelytotheHER2proteinexpressed bysomebreastcancers;thereisnoevidencethatit 
impairsfertility,butpregnancyisnotadvisedduringtreatment. 
9.3Whatadviceshouldbegiventothewomanaboutpostponement ofpregnancybeforeembar kingonfurther 
pregnancy?
Womenaregenerallyadvisedtopostponepregnancy foratleast2yearsaftertreatment andmaybeadvised 
tocontinuetamoxifenfor5years.However,ageisamajordeterminantoffertilityanddelaywithalready 
poorovarianfunctionowingtochemotherapy islikelytoleadtoinfertility.Womenintheir30sdesiring 
pregnancymaywishtodiscussthevalueofprolonged treatmentwithtamoxifenandconsider discontin -
uationafter2–3years.Resumingtreatmentwithtamoxifenafterchildbearinghasnotbeenstudied ,butit 
isareasonablestrategy. 
9.4 Canfertilitybepreservedbeforetreatment? 
Thereisarapidly growingliteratureonpreservationoffertilitypotentialbeforechemotherapy.Atpresent ,
onlyaminorityofwomenofreproductiveageundertakefertility -preservationproceduresandthereare 
scarcelyanydataonlong -termoutcome.
9.4.1GnRHanalogues 
Thereareinsufficientlevel1datatosupport theroutineuseofGnRHanaloguesfor 
ovarianprotectioninestrogenreceptorpositivebreastcancer .
GnRHanalogueshavetherapeuticuseinhormone-sensitiv ebreastcancer,astheyinduce 
profoundovariansuppressio nandcreatealow-estrogen state.Trialsareinprogresstoexamine 
theeffectonfertilitypotential,althoughthereareconcernsthatconcomitantGnRHanalogues 
maylessentumourresponsetochemotherapyinestrogen receptorpositivebreastcancer.There 
areseveralobservationalandphaseIIstudiesoftheuseofGnRHanalogues duringchemo-
therapywiththeintentionofprotectingtheoocytepoolfromdepletion .73 Non-randomised 
studiesinwomenwithbreastcancer(totaln=222)aresuggestiveofbenefit .74–76 
Arecentlyreportedrandomisedcontrolledtrialinpremenopausalwomenwithbreastcancer 
foundthatco-treatmentwithGnRHanaloguesduringchemotherapylessenedtheriskofovarian 
damage(35/39resumedmensesversus 13/39,P<0.001). 77 Theuncertaintiescanbediscussed 
withthewomanbythetreatingoncologist .
9.4.2Cryopreservation 
Ovarianstimulationforeggorembryofreezing requires carefuldiscussioninlightof 
unknownlong-termrisks.Modified stimulationregimes shouldbeconsidered for 
womenwithestrogen-sensitivebreastcancer. 
©RoyalCollegeofObst etriciansandGynaecologists 9of15 RCOGGreen-topGuidelineNo.12 Evidence 
level3 
/check
Evidence 
level3 
Evidence 
level1+ 
/checkEmbryocryopreservationisawell established techniquewithsuccessratesofatleast20%per 
cycle ,78 althoughitispossiblethatsuccessratesmaybelowerwhenoocytesareretrievedfrom 
womenwithcancer. Thetimerequiredforovarianstimulationandeggharvestmaypostpone 
chemotherapy,andthereisasmallriskofproceduralcomplicationssuchasovarianhyperstim -
ulation.Thereisconcernthatelevatedestrogenlevelsmaybedeleteriousinestrogenreceptor 
positivebreastcancer;tominimisethisrisk,stimulation regimenswithtamoxifen orletrozole, 
usuallycombinedwithgonadotrophins,areproposed .79,80 
Oocytestoragemaybeofferedtowomenwithoutapartner.Freeze –thawtechniquesarerapidly 
improving ,buttherehavebeenonlyafewhundred birthsworldwideafteruseofthistechnique 
andtherearenolong-termsafetydata.Harvesting immatureoocyteswithout requiringa 
hormone-stimulatedcycleisanattractiveproposition ,butisnotanestablishedtechnique .81 
Thereareinsufficientdatatosupport ovariantissuestorageforfertilitypreservation 
inwomenwithbreastcancer;thisshouldbeofferedonlyinthecontextofaresearch 
trial. 
Cryopreservationofovariancortexorthewholeovaryhasresultedinasmallnumber of 
pregnanciesafterregrafting .82 Thisremainsanexperimentaltechniqueandtissuestorage 
regulationsintheUKhaverestricteditsuse.Theneedforasurgicalprocedureisadisadvantage , 
butthistechniquedoesnotdelaychemotherapy. 
Everybreastoncologyserviceshouldhaveadesignate dpathwayforpromptreferral 
toafertilityspecialistabletoofferassistedconception; serviceprovisionshouldnot 
bedependentonlocalinvitrofertilistionfunding arrangem ents. 
Theorganisationalaspectsofthe expanding breastoncology serviceneedtobeaddressed.Promptreferral 
isessential;preparationsforeggretrievalcanbeinstigatedduringbreastcancerdiagnostic procedures 
andsurgerytominimisedelaysinstartingsystemictreatment.TheNationalInstituteforHealthandClinical 
Excellence 83 recommendeduniversalaccesstosperm,eggandembryostorageforpeopleundergoing 
gonadotoxictreatment.However,NHSfundingisnotavailableinallareas,andisdependent uponthe 
primarycaretrustandthelocalinfertilitybudget.Theoncology referralpathwayinthecancernetwork 
doesnotnecessarilycoincidewithlocalinvitrofertilisation arrangements.ThejointRoyalCollegesworking 
partyrecommendedthatadequatefundingshouldbemadeavailable. 68 
9.5Assistedreproduct ionaftertreatmentforbreast cancer 
Fertilitytreatmentafterchemotherapyislimitedbylossofovarianreserve .84,85 Thestimulationaspectof 
invitrofertilisationcarriesatheoreticalriskasitisahyperestrogenicstate,althoughofshorterduration 
thanpregnancy. Womenwhohavechemotherapy -inducedmenopausecanbecomepregnantwithdonated 
eggs;thisrequiresshort-termhormonereplacement therapy,whichagaincarriesatheoretical risk. 
Replacementofcryopreservedembryosisalsoperformed inamedicatedhormonereplacem enttherapy 
cycle.Womenforwhompregnancyiscontraindicated maywishtoconsidersurrogacy. 
RCOGGreen-topGuidelineNo.12 10 of15 ©RoyalColle geofObste tricians andGynaecologis ts Evidence 
level3 Evidence 
level2+ 
Evidence 
level3 
/checkD10. Sugge stedaudittopics 
Relativelyfewwomenpresentwithpregnancyduringoraftertreatmentforbreastcancer.
Oncologistsmaywishtoaudit :
Gwhatpercentageof youngwomentreatedforbreastcancerhavebeengiveninformationon
contraceptionandfuturepregnancy
Goutcomeofreferralstoafertilityspecialist .
Gynaecologistsmaywishtoaudit :
Goutcomeofreferralsforfertilitypreservation .
References 
©RoyalCollegeofObst etriciansandGynaecologists 11 of15 RCOGGreen-topGuidelineNo.12 1. SmithLH,DanielsenB,AllenME,CressR.Cancer 
associatedwithobstetricdelivery:resultsoflinkagewith 
theCaliforniacancerregistry.AmJObstetGynecol
2003;189:1128–35.
2. AnderssonTM ,JohanssonAL ,HsiehCC ,Cnattingius S ,
LambeM .Increasingincidenceofpregnancy-associated 
breastcancerinSweden.ObstetGynecol2009; 
114:568–72. 
3. EarlyBreastCancerTrialists ’CollaborativeGroup 
(EBCTCG ).Effectsofchemotherapyandhormonal 
therapyforearlybreastcanceronrecurrenceand15-year 
survival:anoverviewoftherandomisedtrials.Lancet 
2005;365:1687–717. 
4. AssociationofBreastSurgeryatBaso 2009 .Surgical 
guidelinesforthemanagementofbreastcancer. 
EurJSurgOncol2009;35 Suppl1:s1 .1–22.
5. KromanN,JensenMB,WohlfarhrtJ,EjlertsenB;Danish 
BreastCancerCooperativeGroup.Pregnancy after 
treatmentofbreastcancer–apopulatio n-basedstudyon 
behalfofDanishBreastCancerCooperative Group. Acta 
Oncol2008;47:545–9. 
6. IvesA,SaundersC,BulsaraM,SemmensJ.Pregnancyafter 
breastcancer:populationbasedstudy.BMJ 2007;334:194. 
7. BraunM ,Hasson-OhayonI,PerryS,KaufmanB,UzielyB. 
Motivationforgivingbirthafterbreastcancer. 
Psychooncology 2005;14:282–96. 
8. ConnellS,PattersonC,NewmanB.Aqualitative analysis
ofreproductiveissuesraisedbyyoungAustralianwomen 
withbreastcancer.HealthCareWomenInt2006; 
27:94–110. 
9. PeateM,MeiserB,HickeyM,FriedlanderM.Thefertility-
relatedconcerns,needsandpreferencesofyounger 
womenwithbreastcancer:asystematicreview.Breast 
CancerResTreat2009;116:215–23. 
10. BeadleBM,Woodward WA,MiddletonLP,TereffeW,Strom 
EA,LittonJK,etal.Theimpactofpregnancy onbreast 
canceroutcomesinwomen≤35years.Cancer 
2009;115:1174–84. 
11. RodriguezAO,ChewH,CressR,XingG,McElvyS, 
DanielsenB,etal.Evidenceofpoorersurvivalin 
pregnancy-ass ociatedbreastcancer.ObstetGynecol
2008;112:71–8. 
12. MiddletonLP,AminM,GwynK,Theriault R,SahinA.Breast 
carcinomainpregnantwomen:assessmentof 
clinicopathologicandimmunohi stochemicalfeatures. 
Cancer 2003;98:1055–60. 
13. WebbJA,ThomsenHS,MorcosSK;MembersofContrast 
MediaSafetyCommitteeofEuropean Societyof 
UrogenitalRadiology(ESUR).Theuseofiodinatedand 
gadoliniumcontrastmediaduringpregnancy and 
lactation.EurRadiol2005;15:1234–40. 
14. SpanheimerPM,GrahamMM,SuggSL,Scott-ConnerCE, 
WeigelRJ. Measurementofuterineradiationexposure 
fromlymphoscintigraphyindicatessafetyofsentinel 
lymphnodebiopsyduringpregnancy.AnnSurgOncol
2009;16:1143–7. 15. GiacalonePL,LaffargueF,BénosP.Chemotherapyfor 
breastcarcinomaduringpregnancy:aFrenchnational 
survey.Cancer 1999;86:2266–72. 
16. RingAE,SmithIE,JonesA,ShannonC,GalaniE,EllisPA. 
Chemotherapyforbreastcancerduringpregnancy:an
18-yearexperiencefromfiveLondonteachinghospitals. 
JClinOncol2005;23:4192–7. 
17. HahnKM,JohnsonPH,GordonN,KuererH,MiddletonL, 
RamirezM,etal.Treatmentofpregnantbreastcancer 
patientsandoutcomesofchildrenexposedto 
chemotherapyinutero.Cancer 2006;107:1219–26. 
18. GwynK.Childrenexposedtochemotherapyinutero. 
JNatlCancerInstMonogr 2005;(34):69–71. 
19. WatsonWJ.Herceptin(trastuzumab)therapyduring 
pregnancy:associationwithreversibleanhydramnios. 
Obstet Gynecol2005;105:642–3. 
20. MirO,BerveillerP,RopertS,GoffinetF,PonsG,TreluyerJM, 
etal.Emergingtherapeuticoptionsforbreastcancer 
chemotherapyduringpregnancy.AnnOncol
2008;19:607–13. 
21. AvilésA,NeriN .Haematologicalmalignanciesand 
pregnancy :afinalreportof84childrenwhoreceived 
chemotherapyinutero. Clin Lymphoma 2001;2:173–7. 
22. EganPC,CostanzaME,DodionP,EgorinMJ,BachurNR. 
Doxorubicinandcisplatinexcretionintohumanmilk. 
CancerTreatRep 1985;69:1387–9. 
23. LeungAKC,SauveRS.Breastisbestforbabies.JNatlMed 
Assoc 2005;97:1010–9. 
24. GaffieldME,CulwellKR.Newrecommendations onthe 
safetyofcontraceptivemethodsforwomenwithmedical 
conditions:WorldHealthOrganization’sMedical
eligibilitycriteriaforcontraceptiveuse,fourthedition .
IPPFMedicalBulletin2010;44(1)[ http://www.ippf.org/ 
NR/rdonlyres/D67E0B0E-39C 9-4A0A-99E7-
44AD870C5058/0/MedBullEnglishMar2010.pdf ]. 
25. Breastcancerandhormona lcontraceptives:collaborative 
reanalysisofindividualdataon53 297womenwithbreast 
cancerand100 239womenwithoutbreastcancerfrom 
54epidemiologicalstudies .CollaborativeGroupon 
HormonalFactorsinBreastCancer. Lancet 
1996;347:1713–27. 
26. HannafordPC,SelvarajS,ElliottAM,AngusV,IversenL ,Lee 
AJ .Cancerriskamongusersoforalcontraceptives:cohort 
datafromtheRoyalCollegeofGeneralPractitioner ’soral 
contraceptionstudy.BMJ 2007;335:651. 
27. ChanSS,TamWH,YeoW,YuMM,NgDP,WongAW,etal. A
randomisedcontrolledtrialofprophylacticlevonorgestrel 
intrauterinesystemintamoxifen-treatedwomen.BJOG 
2007;114:1510–5. 
28. TrinhXB,TjalmaWA,MakarAP,BuytaertG,WeylerJ,van 
DamPA.Useofthelevonorgestrel-releasingintrauterine 
systeminbreastcancerpatients.FertilSteril2008;90: 
17–22. 
29. CalhounK ,HansenN.Theeffectofpregnancyonsurvival 
inwomenwithahistoryofbreastcancer.BreastDis 
2005;23:81–6. 30. BarthelmesL ,DavidsonLA,GaffneyC,GateleyCA. 
Pregnancyandbreastcancer.BMJ 2005;330:1375–8 . 
31. VelentgasP,DalingJR,MaloneKE,WeissNS,WilliamsMA, 
SelfSG,etal. Pregnancyafterbreastcarcinoma:outcomes 
andinfluenceonmortality. Cancer 1999;85:2424–32 . 
32. GelberS,CoatesAS,GoldhirschA,Castiglione-GertschM, 
MariniG,Lindtner J ;InternationalBreastCancerStudy 
Group. Effectofpregnancyonoverallsurvivalafterthe 
diagnosisofearly-stagebreastcancer. JClinOncol
2001;19:1671–5. 
33. vonSchoultzE,JohanssonH,WilkingN,RutqvistLE. 
Influenceofpriorandsubsequentpregnancy onbreast 
cancerprognosis. JClinOncol1995;13:430–4. 
34. BlakelyLJ,BuzdarAU,LozadaJA,ShullaihSA,HoyE,Smith 
TL ,etal.Effectsofpregnancy aftertreatmentforbreast 
carcinomaonsurvivalandriskofrecurrence.Cancer 
2004;100:465 –9. 
35. MuellerBA,SimonMS,DeapenD,Kamineni A,MaloneKE, 
DalingJR.Childbearingandsurvivalafterbreast 
carcinomainyoungwomen.Cancer 2003;98:1131– 40. 
36. SankilaR,Heinävaar aS,HakulinenT.Survivalofbreast 
cancerpatientsaftersubsequenttermpregnancy :“healthy 
mothereffect ”.AmJObstetGynecol1994;170:818–23. 
37. PetrekJ,SeltzerV.Breastcancerinpregnant and 
postpartumwomen .JObstetGynaecolCan 2003;25: 
944–50. 
38. AndrieuN,GoldgarDE,EastonDF,RookusM,BrohetR, 
AntoniouAC,etal;EMBRACE;GENEPSO; IBCCS 
CollaboratorsGroup.Pregnancies,breast-feeding,
andbreastcancerriskintheInternationalBRCA1/2 
CarrierCohortStudy(IBCCS).JNatlCancerInst 
2006;98:535–44. 
39.SocietyofObstetriciansandGynaecologistsofCanada. 
ClinicalpracticeGuidelineNo. 111:Breastcancer,
pregnancy,andbreastfeeding .Ottawa:SOGC;2002 
[http://www.sogc.org/guidelines/public/111E -CPG-
February2002.pdf ]. 
40. IsaacsJH. Cancerofthebreastinpregnancy. SurgClin 
NorthAm1995;75:47–51. 
41. GwynK,TheriaultR. Breastcancerduringpregnancy .
Oncology(WillistonPark) 2001;15:39–46;discussion 46 ,
49–51. 
42. SaphnerT,TormeyDC,GrayR. Annualhazardratesof 
recurrenceforbreastcancerafterprimarytherapy. 
JClinOncol1996;14:2738–46. 
43. AveretteHE,MirhashemiR,MoffatFL. Pregnancy after 
breastcarcinoma:theultimatemedicalchallenge .Cancer 
1999;85:2301–4.
44. HickeyM,PeateM,SaundersCM,FriedlanderM .Breast 
cancerinyoungwomenanditsimpactonreproductive 
function.HumReprodUpdate 2009;15:323–39. 
45. DelMastroL,CatzedduT,VenturiniM.Infertilityand 
pregnancyafterbreastcancer:currentknowledgeand 
futureperspectives.CancerTreatRev 2006;32:417– 22. 
46. BlakelyLJ,BuzdarAU,LozadaJA,ShullaihSA,HoyE,Smith 
TL ,etal.Effectsofpregnancy aftertreatmentforbreast 
carcinomaonsurvivalandriskofrecurrence.Cancer 
2004;100:465–9. 
47. MulvihillJJ,McKeenEA,RosnerF,ZarrabiMH. Pregnancy 
outcomeincancerpatients.Experienceinalarge 
cooperativegroup .Cancer 1987;60:1143–50. 
48. SuttonR,BuzdarAU,HortobagyiGN. Pregnancy and 
offspringafteradjuvant chemothe rapyinbreastcancer 
patients .Cancer 1990;65:847–50. 
49. LangagergaardV,GislumM,SkriverMV,NørgårdB,LashTL, 
RothmanKJ ,etal.Birthoutcomeinwomenwithbreast 
cancer.BrJCancer 2006;94:142–6. 
50. DalbergK,ErikssonJ,HolmbergL .Birthoutcomein 
womenwithpreviouslytreatedbreastcancer –a
population-bas edcohortstudyfromSweden.PLoSMed 
2006;9 :e336. 
51. HershmanDL,ShaoT. Anthracyclinecardiotoxicityafter 
breastcancertreatment. Oncology(WillistonPark) 
2009;23:227–34. 
52. ShanK,LincoffAM,YoungJB.Anthracycline-induced 
cardiotoxicity.AnnInternMed1996;125:47–58. 53. vanDalenEC,vanderPalHJ,vandenBosC,KokWE, 
CaronHN,KremerLC. Clinicalheartfailureduring 
pregnancyanddeliveryinacohortoffemalechildhood 
cancersurvivorstreatedwithanthracyclines .EurJ 
Cancer2006;42:2549–53. 
54. HigginsS,HafftyBG. Pregnancyandlactationafterbreast-
conservingtherapyforearlystagebreastcancer .Cancer 
1994;73:2175–80. 
55. TralinsAH .Lactationafterconservativebreastsurgery 
combinedwithradiationtherapy .AmJClinOncol
1995;18:40–3. 
56. MoranMS,ColasantoJM,HafftyBG,WilsonLD,LundMW, 
HigginsSA. Effectsofbreast-conservingtherapyon 
lactationafterpregnancy.CancerJ 2005;11:399– 403. 
57. VarsosG,YahalomJ. Lactationfollowingconservation 
surgeryandradiotherapyforbreastcancer. JSurgOncol
1991;46:141–4. 
58. AzimHAJr,BellettiniG,GelberS,PeccatoriFA.Breast-
feedingafterbreastcancer:ifyouwish,madam.Breast 
CancerResTreat 2009;14:7–12.
59. CamuneB,GabzdylE.Breast-feedingafterbreastcancerin 
childbearingwomen .JPerinatNeonatalNurs 
2007;21:225–33. 
60. PartridgeAH,GelberS,PeppercornJ,SampsonE,Knudsen 
K,Laufer,M,etal.Web-basedsurveyoffertilityissuesin 
youngwomenwithbreastcancer.JClinOncol
2004;22:4174–83. 
61. BraunM,Hasson-Ohayon I,PerryS,KaufmanB,UzielyB. 
Motivationforgivingbirthafterbreastcancer. 
Psychooncology 2005;14:282–96. 
62. ConnellS,PattersonC,NewmanB .Aqualitativeanalysisof 
reproductiveissuesraisedbyyoungAustralianwomen 
withbreastcancer.HealthCareWomenInt 2006; 
27:94–110. 
63. PeateM,MeiserB,HickeyM,FriedlanderM. Thefertility-
relatedconcerns,needsandpreferencesof younger 
womenwithbreastcancer:asystematicreview.Breast 
CancerResTreat 2009;116:215–23. 
64. ThewesB,MeiserB,RickardJ,FriedlanderM.Thefertility-
andmenopause-relatedinformationneedsofyounger 
womenwithadiagnosisofbreastcancer:aqualitative 
study.Psychooncology 2003;12:500–11. 
65. KnobfMT.Themenopausalsymptomexperienceinyoung 
mid-lifewomenwithbreastcancer.CancerNurs 
2001;24:201–10. 
66. DunnJ,StegingaSK.Youngwomen’sexperienceofbreast 
cancer:definingyoungandidentifyingconcerns. 
Psychooncology 2000;9:137–46.
67. ThewesBM.Fertility-andmenopause-relatedinformation 
needsofyoungerwomenwithadiagnosisofearlybreast 
cancer.JClinOncol2005;23:5155–65.
68. RoyalCollegeofPhysicians,TheRoyalCollegeof 
Radiologists,RoyalCollegeofObstetriciansand 
Gynaecologists.Theeffectsofcancertreatmenton 
reproductivefunctions .Guidanceonmanagement.
ReportofaWorkingParty.London:RCP ;2007 
[http://bookshop.rcplondon. ac.uk/contents/ 
pub238-5e88e6e4-d9d0-4e99-a2f9-b1bea2daf562.pdf ]. 
69. MintonSE,MunsterPN.Chemotherapy-induced 
amenorrheaandfertilityinwomenundergoingadjuvant 
treatmentforbreastcancer.CancerControl2002;9: 
466–72. 
70. BinesJ,OleskeDM,CobleighMA.Ovarianfunctionin 
premenopausalwomentreatedwithadjuvant 
chemotherapyforbreastcancer. JClinOncol
1996;14:1718–29. 
71. ZekriJM,El-HelwLM,PurohitOP,HattonMQ,ColemanRE. 
Epirubicin/vinorelbineadjuvantchemotherapyinyoung 
womenwithbreastcancerisassociatedwithpreservation 
ofmenstrualfunction. ClinOncol(RCollRadiol) 
2008;20:513–6. 
72. MinisiniAM,MenisJ,ValentF,AndreettaC,AlessiB, 
PascolettiG,etal.Determinantsofrecoveryfrom 
amenorrheainpremenopausalbreastcancerpatients 
receivingadjuvantchemotherapyinthetaxaneera. 
AnticancerDrugs 2009;20:503–7. 
RCOGGreen-topGuidelineNo.12 12 of15 ©RoyalColle geofObste tricians andGynaecologis ts 73. BlumenfeldZ.Howtopreservefertilityinyoungwomen 
exposedtochemotherapy?TheroleofGnRHagonist 
cotreatmentinadditiontocryopreservationofembrya, 
oocytes,orovaries.Oncologist 2007;12:1044–54. 
74. MaltarisT,WeigelM,MuellerA,SchmidtM,SeufertR,Fischl 
F,etal.Cancerandfertilitypreservation:fertility 
preservationinbreastcancerpatients.BreastCancerRes 
2008;10:206. 
75. RecchiaF,SaggioG,AmiconiG,DiBlasioA,CestaA, 
CandeloroG ,etal.Gonadotropi n-releasinghormone 
analoguesaddedtoadjuvant chemotherapyprotect 
ovarianfunctionandimproveclinicaloutcomesinyoung 
womenwithearlybreastcarcinoma.Cancer 
2006;106:514–23. 
76. MaisanoR,CaristiN,MareM,BottariM,AdamoV,Mafodda 
A,etal .Protectiveeffectofleuprolideonovarianfunction 
inyoungwomentreatedwithadjuvant chemotherapyfor 
earlybreastcancer:amulticenterphaseIIstudy. 
JChemother 2008;20:740–3. 
77. BadawyA,ElnasharA,El-AshryM,ShahatM.Gonadotropin-
releasinghormoneagonistsforprevention of 
chemotherapy-inducedovariandamage:prospective 
randomizedstudy.FertilSteril2009;91:694–7. 
78. HumanFertilisation&EmbryologyAuthority.Codeof 
Practice.London:HFEA ;2009[http://www.hfea.gov.uk/ 
code.html]. 
79. OktayK,BuyukE,LibertellaN,AkarM,Rosenwaks Z. 
Fertilitypreservationinbreastcancerpatients:a 
prospectivecontrolledcomparisonofovarianstimulation 
withtamoxifenandletrozole forembryo 
cryopreservation. JClinOncol2005;23:4347–53. 80. OktayK,HourvitzA,SahinG,OktemO,SafroB,CilA,etal. 
Letrozolereducesestrogenandgonadotropin exposurein 
womenwithbreastcancerundergoingovarian 
stimulationbeforechemotherapy.JClinEndocrinol
Metab2006;91:3885–90. 
81. DemirtasE,ElizurSE,HolzerH,GidoniY,SonWY,Chian 
RC,etal .Immatureoocyteretrievalinthelutealphaseto 
preservefertilityincancerpatients.ReprodBiomed 
Online 2008;17:520–3. 
82. DonnezJ,Martinez-MadridB,JadoulP ,VanLangendonc ktA ,
DemylleD ,DolmansMM .Ovariantissuecryopreservation 
andtransplantation:areview.HumReprodUpdate 
2006;12:519–35. 
83. NationalInstituteforHealthandClinicalExcellence. 
Assessmentandtreatmentforpeoplewithfertility 
problems .London:NICE ;2004[ http://www. 
nice.org.uk/nicemedia/pdf/CG011publicinfoenglish.pdf ].
84. LutchmanSinghK,MuttukrishnaS,SteinRC,McGarrigle 
HH,PatelA, ParikhB,etal.Predictorsofovarianreservein 
youngwomenwithbreastcancer. BrJCancer 
2007;96:1808–16.
85. AndersonRA,ThemmenAP,Al-QahtaniA,GroomeNP, 
CameronDA.Theeffectsofchemotherapyandlong-term 
gonadotr ophinsuppressionontheovarianreservein 
premenopausalwomenwithbreastcancer.HumReprod 
2006;21:2583–92. 
©RoyalCollegeofObst etriciansandGynaecologists 13 of15 RCOGGreen-topGuidelineNo.12 Appendix 
RCOGGreen-topGuidelineNo.12 14 of15 ©RoyalColle geofObste tricians andGynaecologis ts Gradesofrecomme ndations 
Atleastonemeta-analysis,systematicreviewor 
randomisedcontrolledtrialratedas1++and 
directlyapplicabletothetargetpopulation;or
Asystematicreviewofrandomisedcontrolled 
trialsorabodyofevidenceconsisting 
principallyofstudiesratedas1+directly 
applicabletothetargetpopulationand 
demonstratingoverallconsistencyofresults 
Abodyofevidenceincludingstudiesratedas 
2++directlyapplicabletothetarget 
population,anddemonstratingoverall 
consistencyofresults;or
Extrapolatedevidencefromstudiesratedas 
1++or1+ 
Abodyofevidenceincludingstudiesratedas 
2+directlyapplicabletothetargetpopulation 
anddemonstratingoverallconsistencyof 
results;or
Extrapolatedevidencefromstudiesratedas 
2++ 
Evidencelevel3or4;or
Extrapolatedevidencefromstudiesratedas2+ 
Goodpracticepoint 
Recommendedbestpracticebasedonthe 
clinicalexperienceoftheguideline 
developmentgroup Class ificationofevidence levels 
1++ High-qualitymeta-analyses,systematic 
reviewsofrandomisedcontrolledtrials 
orrandomisedcontrolledtrialswitha 
verylowriskofbias 
1+ Well-conductedmeta-analyses,systematic 
reviewsofrandomisedcontrolledtrials 
orrandomisedcontrolledtrialswitha 
lowriskofbias 
1– Meta-analyses,systematicreviewsof 
randomisedcontrolledtrialsor 
randomisedcontrolledtrialswithahigh 
riskofbias 
2++ High-qualitysystematicreviewsofcase– 
controlorcohortstudiesorhigh-quality 
case–controlorcohortstudieswitha 
verylowriskofconfounding,biasor 
chanceandahighprobabilitythatthe 
relationshipiscausal 
2+ Well-conductedcase–controlorcohort 
studieswithalowriskofconfounding, 
biasorchanceandamoderate 
probabilitythattherelationshipiscausal 
2-Case–controlorcohortstudieswitha 
highriskofconfounding,biasorchance 
andasignificantriskthattherelationship 
isnotcausal 
3Non-analyticalstudies,e.g.casereports, 
caseseries 
4Expertopinion /checkC
DBA©RoyalCollegeofObst etriciansandGynaecologists 15 of15 RCOGGreen-topGuidelineNo.12 DISCLAIMER 
TheRoyalCollegeofObstetriciansandGynaecolog istsproducesguidelinesasaneducationalaidtogoodclinicalpractice. 
Theypresentrecognisedmethodsandtechniquesofclinicalpractice,basedonpublished evidence,forconsideration by 
obstetriciansandgynaecologistsandotherrelevanthealthprofession als.Theultimatejudgement regardingaparticular 
clinicalprocedureortreatmentplanmustbemadebythedoctororotherattendant inthelightofclinicaldatapresented 
bythepatientandthediagnosticandtreatment optionsavailable.ThismeansthatRCOGguidelines areunlikeprotocols 
orguidelinesissuedbyemployers,astheyarenotintendedtobeprescriptivedirections definingasinglecourseof 
management.Departurefromthelocalprescriptiveprotocols orguidelines shouldbefullydocumen tedinthepatient’s 
casenotesatthetimetherelevantdecisionistaken. Theguidelinesreviewprocesswillcommencein2014, unlessevidencerequiresearlierreview ThisguidelinewasproducedonbehalfoftheGuidelines Committee oftheRoyalCollegeofObstetricians and
Gynaecologistsby:
MsMCDaviesFRCOG,LondonandDrALJones,UCLHFoundationTrust,CancerManagement,London 
andpeerreviewedby:AssociationofBreastSurgery;BritishMaternalandFetalMedicine Society;BreastCancerCare; 
RCOGConsumers’Forum; ProfessorJMDixon,ProfessorofSurgeryandConsultant Surgeon,WesternGeneralHospital, 
Edinburgh,Scotland ;DrAHDDiyafMRCOG,Birmingham; DrAFrancis,ConsultantBreastSurgeon,University Hospital 
Birmingham; ProfessorABMacLeanFRCOG,London;ProfessorJLansac FRCOG,France;ProfessorPSauven,Professor 
ofSurgicalOncology,BroomfieldHospital,Chelmsfor d,UK .
Committeeleadpeerreviewerswere:DrKHardingFRCOG,LondonandDrNASiddiquiFRCOG,Glasgow,Scotland .
Conflictsofinterest :nonedeclared 
ThefinalversionistheresponsibilityoftheGuidelinesCommitteeoftheRCOG.